Aminolevulinic acid (ALA)

Overview

Aminolevulinic acid (ALA), also known as δ-ALA or 5-ALA, is an endogenous non-proteinogenic amino acid and the first compound formed in the porphyrin synthesis pathway. This pathway leads to heme production in mammals. ALA is formed in the liver from glycine and succinyl-CoA through the action of ALA synthase, a rate-limiting enzyme responsible for regulating the porphyrin metabolic cycle. ALA is present in both mitochondria and cytoplasm and is essential for normal heme synthesis, oxygen transport, detoxification, electron transfer through cytochromes, and cellular respiration.

The document explains that abnormalities in Aminolevulinic acid production or metabolism significantly impact cellular energy, neurological health, and overall metabolic balance. ALA also serves therapeutic and diagnostic purposes, including use in photodynamic detection, neurosurgery for glioma resection, and topical treatment of actinic keratosis through photodynamic therapy. Aminolevulinic acid levels are clinically measured using urine, plasma, or serum samples to assess disorders related to porphyrin and heme synthesis.

Symptoms

Aminolevulinic acid itself does not directly produce symptoms; however, abnormal Aminolevulinic acid levels reflect underlying metabolic disorders, especially porphyrias and toxin exposures.

Symptoms associated with high ALA levels may include:

1. Neurological symptoms such as confusion, neuropathy, and irritability
2. Abdominal pain, which is frequently linked with acute porphyrias
3. Behavioral changes or cognitive disturbances, especially in lead poisoning
4. Photosensitivity and skin issues, depending on the type of porphyria
5. Generalized weakness or fatigue due to impaired heme synthesis

Symptoms associated with low ALA levels may include:

1. Manifestations of chronic liver disease
2. Metabolic dysfunction caused by insufficient activity of Aminolevulinic acid dehydratase, as seen in rare enzymatic disorders

The document highlights that high or low ALA levels should always be interpreted within the context of the metabolic or toxic condition affecting heme synthesis.

Causes

Abnormal ALA levels arise when porphyrin and heme synthesis pathways are disrupted.

Causes of increased ALA include:

1. Exposure to alcohol, which raises ALA levels due to impaired metabolism
2. All acute porphyrias, including acute intermittent porphyria, hereditary coproporphyria, and variegate porphyria
3. Lead poisoning, which inhibits ALA dehydratase and causes ALA accumulation
4. Hereditary tyrosinemia, where metabolic abnormalities result in massive ALA elevation

Causes of decreased ALA include:

1. Chronic liver disease, where impaired liver function affects Aminolevulinic acid synthesis
2. Extremely rare metabolic disorders, such as Doss porphyria, are caused by low activity of Aminolevulinic acid dehydratase

The document also notes that ALA levels may vary due to interference from medications, improper sample handling, or enzyme deficiencies.

Risk Factors

Risk factors are primarily tied to metabolic, toxic, or genetic influences affecting heme synthesis.

High-risk situations for elevated ALA include:

1. Exposure to heavy metals such as lead
2. Family history of genetic porphyrias
3. Use of alcohol or certain medications that disturb porphyrin metabolism
4. Neurological symptoms combined with abdominal pain, which may signal acute porphyria
5. Occupational or environmental exposure to toxins involved in metal or chemical industries

Risk factors for decreased ALA include:

1. Long-standing liver disease
2. Genetic enzyme deficiencies affecting Aminolevulinic acid conversion
3. Conditions impacting ALA dehydratase or downstream porphyrin enzymes

Other procedural risk factors involve sample instability from light and heat, as noted in the document, which can alter measured ALA levels if not properly managed.

Prevention

Prevention focuses on protecting metabolic pathways, ensuring proper sample handling, and reducing exposure to triggers that increase or decrease ALA.

Key preventive strategies include:

1. Avoiding alcohol consumption before testing or in individuals susceptible to porphyrin abnormalities
2. Discontinuing medications known to interfere with ALA levels, such as penicillin, barbiturates, birth control pills, and antifungal agents, under medical supervision
3. Preventing exposure to environmental or occupational toxins, especially lead
4. Managing and monitoring chronic liver disease to prevent decreases in ALA
5. Ensuring correct sample collection procedures, including using clean containers, refrigerating urine samples, and protecting them from light
6. Using validated analytical methods such as HPLC, LC-MS/MS, or ion-exchange chromatography to ensure accurate ALA measurements

Proper monitoring and early recognition of metabolic irregularities help prevent complications associated with disrupted porphyrin and heme synthesis.